Bilaketaren emaitzak - Gil-Gil, Miguel

Bevacizumab for the Treatment of Glioblastoma nork Gil-Gil, Miguel J., Mesia, Carlos, Rey, Montserrat, Bruna, Jordi

Testu osoa Testu osoa Testu osoa

Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer nork Vila, Mireia Margelí, Barco Berron, Sonia del, Gil-Gil, Miguel, Ochoa-Arnedo, Cristian, Vázquez, Rafael Villanueva

Testu osoa Testu osoa Testu osoa

A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive... nork Sánchez‐Rovira, Pedro, Hirschberg, Angelica Lindén, Gil‐Gil, Miguel, Bermejo‐De Las Heras, Begoña, Nieto‐Magro, Concepción

Testu osoa Testu osoa Testu osoa

The role of CDK4/6 inhibitors in early breast cancer nork Gil-Gil, Miguel, Alba, Emilio, Gavilá, Joaquín, de la Haba-Rodríguez, Juan, Ciruelos, Eva, Tolosa, Pablo, Candini, Daniele, Llombart-Cussac, Antonio

Testu osoa Testu osoa Testu osoa

Cognitive and brain structural changes in long-term oligodendroglial tumor survivors nork Cayuela, Nuria, Jaramillo-Jiménez, Esteban, Càmara, Estela, Majós, Carles, Vidal, Noemi, Lucas, Anna, Gil-Gil, Miguel, Graus, Francesc, Bruna, Jordi, Simó, Marta

Testu osoa Testu osoa Testu osoa

Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab(†) nork Balaña, Carmen, Estival, Anna, Pineda, Estela, Sepúlveda, Juan, Mesía, Carles, del Barco, Sonia, Gil-Gil, Miguel, Hardy, Max, Indacoechea, Alberto, Cardona, Andrés Felipe

Testu osoa Testu osoa Testu osoa

Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroida... nork Hirschberg, Angelica Lindén, Sánchez-Rovira, Pedro, Presa-Lorite, Jesús, Campos-Delgado, Miriam, Gil-Gil, Miguel, Lidbrink, Elisabet, Suárez-Almarza, Javier, Nieto-Magro, Concepción

Testu osoa Testu osoa Testu osoa

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study nork Redondo, Andrés, Ramos Vázquez, Manuel, Manso, Luis, Gil Gil, Miguel J, Garau Llinas, Isabel, García-Garre, Elisa, Rodríguez, César A, Chacón, José Ignacio, López-Vivanco, Guillermo

Testu osoa Testu osoa Testu osoa

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center nork Sirvén, Milana Bergamino, Fernández-Ortega, Adela, Stradella, Agostina, Morilla, Idoia, Falo, Catalina, Vázquez, Silvia, Castany, Roser, Villanueva, Rafael, Recalde, Sabela, Pérez, Valentí Navarro, Gil-Gil, Miguel, Pernas, Sonia

Testu osoa Testu osoa Testu osoa

Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis nork Martínez-Aranda, Antonio, Hernández, Vanessa, Moreno, Ferran, Baixeras, Núria, Cuadras, Daniel, Urruticoechea, Ander, Gil-Gil, Miguel, Vidal, Noemí, Andreu, Xavier, Seguí, Miquel A., Ballester, Rosa, Castella, Eva, Sierra, Angels

Testu osoa Testu osoa Testu osoa

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients nork Molina, David, Pérez-Beteta, Julián, Martínez-González, Alicia, Sepúlveda, Juan M., Peralta, Sergi, Gil-Gil, Miguel J., Reynes, Gaspar, Herrero, Ana, De Las Peñas, Ramón, Luque, Raquel, Capellades, Jaume, Balaña, Carmen, Pérez-García, Víctor M.

Testu osoa Testu osoa Testu osoa

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients nork Estival, Anna, Sanz, Carolina, Ramirez, Jose-Luis, Velarde, Jose Maria, Domenech, Marta, Carrato, Cristina, de las Peñas, Ramón, Gil-Gil, Miguel, Sepúlveda, Juan, Armengol, Roser, Cardiel, Isaac, Berrocal, Alfonso, Luque, Raquel, Herrero, Ana, Balana, Carmen

Testu osoa Testu osoa Testu osoa

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution nork Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix

Testu osoa Testu osoa Testu osoa

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single... nork Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix

Testu osoa Testu osoa Testu osoa

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study nork Rosenthal, Mark, Clement, Paul M, Campone, Mario, Gil-Gil, Miguel J, DeGroot, John, Chinot, Olivier, Idbaih, Ahmed, Gan, Hui, Raizer, Jeffrey, Wen, Patrick Yung, Pineda, Estela, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Mason, Warren

Testu osoa Testu osoa Testu osoa

Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial nork Martínez-García, María, Velasco, Guillermo, Pineda, Estela, Gil-Gil, Miguel, Alameda, Francesc, Capellades, Jaume, Martín-Soberón, Mari Cruz, López-Valero, Israel, Tovar Ambel, Elena, Foro, Palmira, Taus, Álvaro, Arumi, Montserrat, Hernández-Laín, Aurelio, Sepúlveda-Sánchez, Juan Manuel

Testu osoa Testu osoa Testu osoa

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Fina... nork Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia

Testu osoa Testu osoa Testu osoa

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification nork Sepúlveda-Sánchez, Juan Manuel, Vaz, María Ángeles, Balañá, Carmen, Gil-Gil, Miguel, Reynés, Gaspar, Gallego, Óscar, Martínez-García, María, Vicente, Elena, Quindós, María, Luque, Raquel, Ramos, Ana, Ruano, Yolanda, Pérez-Segura, Pedro, Benavides, Manuel, Sánchez-Gómez, Pilar, Hernández-Laín, Aurelio

Testu osoa Testu osoa Testu osoa

Pseudoprogression as an adverse event of glioblastoma therapy nork Balaña, Carmen, Capellades, Jaume, Pineda, Estela, Estival, Anna, Puig, Josep, Domenech, Sira, Verger, Eugenia, Pujol, Teresa, Martinez‐García, Maria, Oleaga, Laura, Velarde, JoseMaria, Mesia, Carlos, Fuentes, Rafael, Marruecos, Jordi, Del Barco, Sonia, Villà, Salvador, Carrato, Cristina, Gallego, Oscar, Gil‐Gil, Miguel, Craven‐Bartle, Jordi, Alameda, Francesc

Testu osoa Testu osoa Testu osoa

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma nork Brandes, Alba A., Gil‐Gil, Miguel, Saran, Frank, Carpentier, Antoine F., Nowak, Anna K., Mason, Warren, Zagonel, Vittorina, Dubois, François, Finocchiaro, Gaetano, Fountzilas, George, Cernea, Dana Michaela, Chinot, Oliver, Anghel, Rodica, Ghiringhelli, Francois, Beauchesne, Patrick, Lombardi, Giuseppe, Franceschi, Enrico, Makrutzki, Martina, Mpofu, Chiedzo, Urban, Hans‐Joerg, Pichler, Josef

Testu osoa Testu osoa Testu osoa